Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qidi Gushen capsule is a Traditional Chinese Medicine (TCM) formulation developed by The First Affiliated Hospital of Shaanxi University of Chinese Medicine. It is primarily investigated for the treatment of idiopathic membranous nephropathy (IMN), specifically in patients diagnosed with the TCM syndrome of spleen-kidney qi-yin deficiency. The formulation is typically used as an adjunctive therapy alongside standard Western medical treatments, such as immunosuppressants or ACE inhibitors/ARBs. In TCM theory, the capsule aims to tonify the spleen and kidney while consolidating the essence to reduce proteinuria and stabilize renal function. It is currently being evaluated in real-world clinical studies in China to assess its efficacy and safety in improving clinical outcomes for IMN patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qidi Gushen capsule.